Cangene Corporation today reports that its HepaGam B(R) (Hepatitis B Immune Globulin (Human) Injection) has been approved by the Biologics and Genetic Therapies Directorate of Health Canada for treating acute exposure to hepatitis B virus.
the details can be read here.
No comments:
Post a Comment